Physician profile
Colton Jackson
NPI 1942029152
$8,294.43
in general payments reported to CMS, 2019-2025
26 companies · $8,171 in 2025
The $8,171 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $123 · 2025: $8,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,161 · Travel and Lodging: $3,038 · Consulting Fee: $900 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.82 |
| Travel and Lodging | $3,037.78 |
| Consulting Fee | $900.00 |
| Education | $195.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,815.32 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $2,299.55 | 2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $663.95 | 2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $311.04 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $223.47 | 2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $204.42 | 2025 | Winrevair |
| United Therapeutics Corporation | $194.40 | 2025 | Tyvaso |
| Harmony Biosciences LLC | $187.07 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $174.53 | 2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $146.48 | 2025 | Glassia |
| Grifols USA, LLC | $143.79 | 2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $123.26 | 2024 | Yupelri |
| Verona Pharma, INC. | $111.22 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $105.91 | 2025 | |
| Sanofi-Aventis U.S. LLC | $84.99 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $77.20 | 2025 | Vest Therapy Und |
| Amgen INC. | $73.98 | 2025 | Tezspire |
| Viatris Specialty LLC | $70.15 | 2025 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $62.33 | 2025 | Dupixent |
| Baxter Healthcare | $48.29 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $35.56 | 2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.32 | 2025 | Jascayd, Ofev |
| Liquidia Technologies, INC. | $31.00 | 2025 | Yutrepia |
| 3b Medical, INC. | $29.98 | 2025 | Luna |
| Vifor Pharma, INC. | $23.20 | 2025 | Zemaira |
| Lilly USA, LLC | $22.02 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colton Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.